ClinicalTrials.gg
RecruitingNCT06828393Updated Mar 12, 2025

A Phase 1 Study of S-1117

A Phase 1 interventional study of S-1117 and Placebo in Healthy Volunteer, sponsored by Seismic Therapeutic AU Pty Ltd. Recruiting at 1 site in Australia. Open to participants aged 18 Years to 65 Years, including healthy volunteers. Per ClinicalTrials.gov, last updated 2025-03-12.

Sponsored by Seismic Therapeutic AU Pty Ltd · Phase 1, Interventional, and Treatment

How we know

From the registry’s dates

  • Primary completion was expected by Mar 2026, 8 months ago, but the record still lists the study as recruiting.

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 1
Study type
Interventional
Enrollment
96
Allocation
Randomized
Ages
18 Years to 65 Years
Sex
All
01

Study summary

This is the first-in-human study of S-1117 designed to provide safety, tolerability, pharmacokinetic, and pharmacodynamic data in healthy volunteers.

Read the detailed description

This is a randomized, placebo-controlled, double-blind, study to assess the safety, tolerability, pharmacokinetics and pharmacodynamics of S-1117 administered to healthy adult participants. This study will be conducted in two parts, Part 1 (single ascending dose, SAD) and Part 2 (multiple ascending doses, MAD).

02

Conditions studied

  • Healthy Volunteer
03

In context

Lead sponsor

Seismic Therapeutic AU Pty Ltd is the lead sponsor of 3 studies on the registry; 3 are open to participants now.

Counted across the registry records on this site, refreshed daily.

04

Who can participate

Ages eligible
18 Years to 65 Years
Sexes eligible
All
Accepts healthy volunteers
Yes

Eligibility criteria

Major Inclusion Criteria:

  1. Is available for the entire duration of the study and follow up.
  2. Is willing and able to comply with all study assessments and adhere to the protocol schedule and restrictions.
  3. Voluntarily consents to participation in the trial as documented by signing the study form (ICF).
  4. Has a (BMI) within 18 to 32 kg/m2, inclusive, and weighs ≥45 kg.
  5. Is in good physical and mental health in the opinion of the Investigator or delegate.

Major Exclusion Criteria:

  1. Has a history of severe allergic or anaphylactic reaction as determined by the Investigator or delegate.
  2. Is pregnant, nursing, or is planning to become pregnant or breastfeed during the trial.
  3. Has a known immunodeficiency disorder.
  4. Has a history of other than non-melanoma skin cancer.
  5. Has a history of (HIV) or positive serology for HIV at Screening.
  6. Has positive laboratory evidence for active hepatitis at screening.
  7. Has received a within 2 months of Screening.
  8. Has any other condition or prior therapy that, in the opinion of the Investigator or delegate, may potentially compromise the safety or compliance of the participant, or may preclude the participant from successfully completing the study.

Other inclusion/exclusion eligibility criteria apply.

Terms in these criteria, in plain language(5)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

BMI (body mass index)

Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.

What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.

Cancer (malignancy)

Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.

Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.

HIV

The human immunodeficiency virus, which weakens the immune system.

Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.

Live vaccines

Vaccines made with a weakened form of the germ, such as measles–mumps–rubella (MMR), chickenpox and yellow fever. They can be risky when the immune system is weakened. Flu injections are not live; the nasal flu spray is.

05

Study design

Phase
Phase 1
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Double (Participant, Investigator)
Enrollment
96 participants (estimated)

Study arms

  • Experimental
    S-1117 Part 1: Single ascending dose (SAD) cohorts

    Drug: S-1117 · Other: Placebo

  • Experimental
    S-1117 Part 2: Multiple ascending dose (MAD) cohorts

    Drug: S-1117 · Other: Placebo

Interventions

  • DrugS-1117

    S-1117 via subcutaneous or intravenous administration.

  • OtherPlacebo

    Placebo via subcutaneous or intravenous administration.

06

What researchers measure

Primary outcomes

  1. Number of participants with treatment-related adverse and serious adverse events as assessed by CTCAE v5.0

    Time frame: 2 months

Secondary outcomes

  1. To assess the maximum serum concentration (CMAX)

    Time frame: 2 months

  2. To assess time to reach maximum serum concentration (tMAX)

    Time frame: 2 months

  3. To assess elimination half-life (t1/2)

    Time frame: 2 months

  4. To assess area under the serum concentration-time curve from time 0 to t hours (AUC0-t) and to infinity (AUC0-inf)

    Time frame: 2 months

  5. To assess clearance (CL)

    Time frame: 2 months

  6. To assess volume of distribution (Vz) and steady-state volume of distribution (Vss)

    Time frame: 2 months

  7. To assess bioavailability after SC administration (F%)

    Time frame: 2 months

  8. To characterize absolute and proportional change from baseline of immunoglobulin G (IgG) at multiple timepoints

    Time frame: 2 months

  9. Incidence and characterization of antidrug antibody (ADA)

    Time frame: 2 months

07

Study locations

1 of 1 sites recruiting
08

References and documents

Individual participant data

Plan to share: No — Our IPD sharing plan is not yet developed. We will consider data sharing at a later date.

No publications or documents are linked to this record.

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reached

Start is estimated for Mar 2025; primary completion for Mar 2026, 12 months later.

How these figures are worked out, and which studies are left out of them.

Registered
Jan 20, 2025
First posted
Feb 14, 2025
StartEst.
Mar 2025
Primary completionEst.
Mar 2026
CompletionEst.
Mar 2026
Last update
Mar 12, 2025
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Mar 12, 2025, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT06828393
Lead sponsor
Seismic Therapeutic AU Pty Ltd
Collaborators
Avance Clinical Pty Ltd.
Responsible party
Sponsor
First posted
Feb 14, 2025
Start date
Mar 2025 (estimated)
Primary completion
Mar 2026 (estimated)
Completion
Mar 2026 (estimated)
Last update
Mar 12, 2025

Study contacts

Seismic Contact
Contact
clinical@seismictx.com
1800 244 475

Oversight

Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Interested in this study?

Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.

Contact study team

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion